NR3C2 and obesity due to melanocortin 4 receptor deficiency: Animal studies have demonstrated that treatment with MR antagonists ameliorates vascular remodeling and dysfunction in the setting of CVD risk factors, including aging, western diet-induced obesity and hypertension, without significantly altering blood pressure (49–52), suggesting direct effects of MR antagonism on the vasculature.